You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

CLINICAL TRIALS PROFILE FOR AFINITOR DISPERZ

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for AFINITOR DISPERZ

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04195750 ↗	A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)	Recruiting	Merck Sharp & Dohme Corp.	Phase 3	2020-02-27	The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for AFINITOR DISPERZ

Condition Name

Chart
Table

Condition Name for AFINITOR DISPERZ
Intervention	Trials
Carcinoma, Renal Cell	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for AFINITOR DISPERZ
Intervention	Trials
Carcinoma, Renal Cell	1
Carcinoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for AFINITOR DISPERZ

Trials by Country

Map
Table

Trials by Country for AFINITOR DISPERZ
Location	Trials
United States	22
Japan	12
France	8
Germany	6
United Kingdom	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for AFINITOR DISPERZ
Location	Trials
South Carolina	1
Pennsylvania	1
Oregon	1
Oklahoma	1
Ohio	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for AFINITOR DISPERZ

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for AFINITOR DISPERZ
Clinical Trial Phase	Trials
Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for AFINITOR DISPERZ
Clinical Trial Phase	Trials
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AFINITOR DISPERZ

Sponsor Name

Chart
Table

Sponsor Name for AFINITOR DISPERZ
Sponsor	Trials
Merck Sharp & Dohme Corp.	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for AFINITOR DISPERZ
Sponsor	Trials
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.